Veru to Present at the Jefferies Healthcare Conference
May 24, 2023 08:30 ET
|
Veru Inc.
MIAMI, FL, May 24, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for...
Veru Reports Fiscal 2023 Second Quarter Financial Results
May 11, 2023 06:30 ET
|
Veru Inc.
Agreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatment of hospitalized COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS),...
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS
May 04, 2023 08:30 ET
|
Veru Inc.
Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality at Day 60 Study to expand treatment population to include all...
Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital
May 03, 2023 08:30 ET
|
Veru Inc.
MIAMI, FL, May 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for...
Veru to Report Fiscal 2023 Second Quarter Financial Results on May 11, 2023
April 27, 2023 06:45 ET
|
Veru Inc.
MIAMI, FL, April 27, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related...
Veru Sells ENTADFI® Business for $20 Million Plus up to an Additional $80 Million from Sales Milestones
April 20, 2023 06:45 ET
|
Veru Inc.
MIAMI, FL, April 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related...
Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector
April 19, 2023 08:30 ET
|
Veru Inc.
MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related...
Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses
April 11, 2023 08:30 ET
|
Veru Inc.
Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress...
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe Acute Respiratory Distress Syndrome and Provides Update on COVID-19 Program
April 04, 2023 08:30 ET
|
Veru Inc.
In the final report, sabizabulin significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome (ARDS) in H1N1 influenza pulmonary inflammation murine ARDS model Positive...
Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference
March 07, 2023 08:30 ET
|
Veru Inc.
MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for...